About Holobiome
Holobiome is a company based in Cambridge (United States) founded in 2015. Holobiome has raised $15.59 million across 7 funding rounds from investors including HHS, iSelect Fund and Valor Equity Partners. Holobiome offers products and services including Probiotics Therapies and Targeted Health Solutions. Holobiome operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Novozymes, Neurocrine and PTC Therapeutics, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.59 M (USD)
in 7 rounds
-
Latest Funding Round
$9 M (USD), Seed
Oct 16, 2024
-
Investors
HHS
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Holobiome
Holobiome offers a comprehensive portfolio of products and services, including Probiotics Therapies and Targeted Health Solutions.
Develops microbiome-based products for improving human health and wellness.
Creates targeted therapies from microbiome research for global health applications.
People of Holobiome
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Scientific Team
4 people
Principal Team
1 people
Scientist Team
1 people
Unlock access to complete
Funding Insights of Holobiome
Holobiome has successfully raised a total of $15.59M across 7 strategic funding rounds. The most recent funding activity was a Seed round of $9 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Holobiome
Holobiome has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, iSelect Fund and Valor Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are targeted by iSelect Fund in key sectors.
|
Locked | Locked | Locked | |
|
Private equity firm
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Holobiome
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Holobiome
Investment portfolio details for Holobiome
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Holobiome
Detailed financials for Holobiome
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Holobiome Comparisons
Peer comparison for Holobiome
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Holobiome
Holobiome operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Novozymes, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Holobiome
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Holobiome
Complete news archive for Holobiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Holobiome
Holobiome was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Holobiome is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Holobiome is a funded company, having raised a total of $15.59M across 7 funding rounds to date.
Holobiome was established in 2015 in Cambridge, United States, within the biotechnology sector. A platform focused on microbiome interventions is being advanced to address human disorders, particularly those affecting the nervous system. Therapeutics derived from microbial ecosystems are explored to influence disease progression through targeted microbiome modulation. Operations center on research and development of these biological solutions for therapeutic applications.
Holobiome's top competitors include Jazz Pharmaceuticals, Novozymes and PTC Therapeutics.
Holobiome offers Probiotics Therapies and Targeted Health Solutions.
Holobiome has 8 investors. Key investors include HHS, iSelect Fund, Valor Equity Partners, SkyRiver Ventures, and Satori Capital.